The OmniPod Insulin Management System: the latest innovation in insulin pump therapy

This review of insulin pump therapy focuses on the OmniPod® Insulin Management System (Insulet Corp., Bedford, MA, USA). The OmniPod System is the first commercially available “patch pump.” It is a fully integrated wearable pump, controlled wirelessly through a handheld device containing a built-in blood glucose meter. This is an evaluation of the OmniPod System, with the aim of providing an educational tool for physicians who are considering recommending this product to their patients. The review includes a discussion of the traditional insulin pump configuration and its limitations, a detailed overview of the OmniPod System, references to clinical study data, planned product enhancements, its use as an insulin delivery system in the Juvenile Diabetes Research Foundation’s Artificial Pancreas Project, and its use to deliver additional compounds

Mechanism of completion of peptidyltransferase centre assembly in eukaryotes.

During their final maturation in the cytoplasm, pre-60S ribosomal particles are converted to translation-competent large ribosomal subunits. Here, we present the mechanism of peptidyltransferase centre (PTC) completion that explains how integration of the last ribosomal proteins is coupled to release of the nuclear export adaptor Nmd3. Single-particle cryo-EM reveals that eL40 recruitment stabilises helix 89 to form the uL16 binding site. The loading of uL16 unhooks helix 38 from Nmd3 to adopt its mature conformation. In turn, partial retraction of the L1 stalk is coupled to a conformational switch in Nmd3 that allows the uL16 P-site loop to fully accommodate into the PTC where it competes with Nmd3 for an overlapping binding site (base A2971). Our data reveal how the central functional site of the ribosome is sculpted and suggest how the formation of translation-competent 60S subunits is disrupted in leukaemia-associated ribosomopathies.Bloodwise, MRC, Wellcome Trus

Improved blood glucose control for critically ill subjects

For patients in intensive care units (ICUs), control of blood glucose level is an important factor in reducing serious complications and mortality. Standard protocols for glucose control in ICUs have been based on infrequent glucose measurements, look-up tables to determine the appropriate insulin infusion rates, and bedside administration of the insulin infusion by ICU staff. In this paper a new automatic control strategy is proposed based on frequent glucose measurements and a self-tuning control technique. During a short initial time period when manual glucose control is performed using a standard protocol, a simple dynamic model of the glucose\u2013insulin system is identified in real time using recursive least squares. Then an adaptive PID controller is tuned, based on the model parameters, and the controller is turned on. A simulation study based on detailed physiological models of the glucose\u2013insulin dynamics demonstrates that the proposed control strategy performs better than standard protocols for insulin infusion